AstraZeneca’s Brilinta Fails to Win FDA Approval
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…